X4 Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 24.02 million compared to USD 21.97 million a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.72 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9597 USD | -1.69% | -9.89% | +14.45% |
05-09 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
05-09 | X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.45% | 164M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- XFOR Stock
- News X4 Pharmaceuticals, Inc.
- X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023